Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Array's selumetinib meets in Phase II ocular melanoma

Researchers at Memorial Sloan Kettering Cancer Center presented data at the American Society of Clinical Oncology meeting showing that oral selumetinib from

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE